Roche's New Perjeta Combo Meets Goal in Breast Cancer Study - Yahoo Finance

Roche's New Perjeta Combo Meets Goal in Breast Cancer Study  Yahoo FinanceRoche's (RHHBY) new fixed-dose combination of Perjeta and Herceptin meets the primary endpoint in the phase III study for treating patients with HER2-positive ...